Abstract 6024: A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors

癌症研究 医学 化学
作者
Yoshihide Mizukoshi,Shota Tsuchida,Hiroko Inaba,Tatsuro Kotake,Takanori Aoki,Kai Orihara,Yuichi Funase,Naoki Kanazawa,Hikaru Shimizu,Kaita Sawano,Kentaro Suzuki,Hayato Yanagida,Takeru Ehara,Hidetomo Kitamura,Satoshi Matsushima,Masato Murakami
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 6024-6024
标识
DOI:10.1158/1538-7445.am2024-6024
摘要

Abstract Introduction: Carbonic Anhydrase IX (CA9) is a zinc metalloenzyme that regulates the pH for cell growth. CA9 is considered an attractive target and is upregulated in a variety of cancers, especially, in 95% of clear cell renal cell carcinoma (ccRCC) where there remains a large clinical unmet need despite the availability of several newly approved medicines. PeptiDream has identified PD-32766, a novel macrocyclic peptide, targeting CA9 and can be labeled with radionuclides such as copper (64Cu) and lutetium (177Lu), which enables tumor-specific PET bioimaging and radiotherapy. Here we report the theranostic translational feasibility of PD-32766 for ccRCC. Materials and Methods: PD-32766 was discovered using Peptide Discovery Platform System (PDPS), a proprietary screening system of PeptiDream. Binding affinity of PD-32766, 63Cu-PD-32766 and 175Lu-PD-32766 to CA9 was measured by SPR. For in vivo evaluation, we used a xenograft model in which VMRC-RCW (ccRCC cell line with similar CA9 expression level to clinical samples) was subcutaneously transplanted into nude mice. To assess biodistribution, 64Cu-PD-32766 or 177Lu-PD-32766 was dosed to VMRC-RCW xenograft mice, and the percentage of injected dose in tumors and major organs was quantified by cut and count method. To evaluate whether PET imaging can detect tumors, 64Cu-PD-32766 was dosed to VMRC-RCW xenograft mice and after dosing, PET scanning was performed. For therapeutic experiments, 177Lu-PD-32766 was dosed to VMRC-RCW xenograft mice and tumor volume was measured for 45 days after dosing. Results: SPR analysis revealed that PD-32766, 63Cu-PD-32766 and 175Lu-PD-32766 exhibits an affinity of less than 0.2 nM for CA9. In in vivo biodistribution experiment, 64Cu-PD-32766 and 177Lu-PD-32766 showed specific and strong accumulation in tumors 4 hours after dosing (88 and 107% ID/g, for 64Cu-PD-32766 and 177Lu-PD-32766, respectively) and were highly retained in the tumors at 48 hours after dosing (37 and 51% ID/g, for 64Cu-PD-32766 and 177Lu-PD-32766, respectively). Maximal intensity in other normal tissues were 23 and 9 %ID/g (tumor/kidney=3.8 and 11.9 for 64Cu-PD-32766 and 177Lu-PD-32766, respectively at 4 hrs.). PET bioimaging of 64Cu-PD-32766 clearly detected only tumors, consistent with the biodistribution data. In therapeutic experiments, 177Lu-PD-32766 (30 MBq/mouse single or QW x3) was well tolerated and strikingly improved mouse survival compared with control animals for 45 days after transplantation, which suggests a robust tumor growth inhibition of 177Lu-PD-32766 dosing. Taken together, PD-32766 showed specific tumor accumulation and strong therapeutic effect in a clinically relevant xenograft model of ccRCC. Conclusion: PD-32766 has preferable properties for imaging and therapy with radionuclides and a great potential for theranostic use in ccRCC. Citation Format: Yoshihide Mizukoshi, Shota Tsuchida, Hiroko Inaba, Tatsuro Kotake, Takanori Aoki, Kai Orihara, Yuichi Funase, Naoki Kanazawa, Hikaru Shimizu, Kaita Sawano, Kentaro Suzuki, Hayato Yanagida, Takeru Ehara, Hidetomo Kitamura, Satoshi Matsushima, Masato Murakami. A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6024.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
任性的眼睛完成签到,获得积分10
刚刚
pluto应助红蜻蜓采纳,获得10
1秒前
1秒前
zhaxiao发布了新的文献求助50
1秒前
2秒前
renxy应助AhhHuang采纳,获得10
2秒前
tochege发布了新的文献求助10
2秒前
Rose完成签到,获得积分20
2秒前
彪yu发布了新的文献求助10
2秒前
3秒前
yar应助yKkkkkk采纳,获得10
3秒前
星辰大海应助研友_VZG64n采纳,获得10
3秒前
杭紫雪发布了新的文献求助10
3秒前
xz完成签到 ,获得积分10
3秒前
3秒前
domingo完成签到,获得积分10
4秒前
5秒前
unite 小丘发布了新的文献求助10
5秒前
5秒前
羰醛完成签到 ,获得积分10
5秒前
Akim应助洁净的尔冬采纳,获得10
5秒前
杀死比尔发布了新的文献求助10
6秒前
李爱国应助衡阳采纳,获得10
6秒前
搜集达人应助Frankyu采纳,获得30
6秒前
大力山槐完成签到,获得积分10
6秒前
6秒前
任驰骋发布了新的文献求助10
7秒前
小蘑菇应助七年采纳,获得10
7秒前
7秒前
Orange应助爱听歌依波采纳,获得10
7秒前
樱悼柳雪发布了新的文献求助10
7秒前
xxxL发布了新的文献求助10
8秒前
溯流光完成签到,获得积分10
8秒前
whn完成签到,获得积分20
8秒前
9秒前
Orange应助Yesir采纳,获得10
10秒前
10秒前
爆米花应助猹尔斯采纳,获得10
10秒前
不安太阳发布了新的文献求助10
11秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974463
求助须知:如何正确求助?哪些是违规求助? 3518823
关于积分的说明 11196212
捐赠科研通 3255008
什么是DOI,文献DOI怎么找? 1797655
邀请新用户注册赠送积分活动 877052
科研通“疑难数据库(出版商)”最低求助积分说明 806130